Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors that may predict failure, particularly early...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Vercellino, Laetitia, Di Blasi, Roberta, Kanoun, Salim, Tessoulin, Benoit, Rossi, Cedric, D'Aveni-Piney, Maud, Obéric, Lucie, Bodet-Milin, Caroline, Bories, Pierre, Olivier, Pierre, Lafon, Ingrid, Berriolo-Riedinger, Alina, Galli, Eugenio, Bernard, Sophie, Rubio, Marie-Thérèse, Bossard, Celine, Meignin, Veronique, Merlet, Pascal, Feugier, Pierre, Le Gouill, Steven, Ysebaert, Loic, Casasnovas, Olivier, Meignan, Michel, Chevret, Sylvie, Thieblemont, Catherine
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686887/
https://ncbi.nlm.nih.gov/pubmed/33180899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars